Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Conditions
- Metastatic Castration-Sensitive Prostate Cancer
- Interventions
- Registration Number
- NCT06120491
- Lead Sponsor
- AstraZeneca
- Brief Summary
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
- Detailed Description
Approximately 1800 adult participants with mCSPC will be assigned to one of two cohorts (550 HRRm and 1250 non-HRRm) and randomized in a 1:1 ratio to receive either Saruparib (AZD5305) with NHA or placebo with NHA. They will receive their assigned treatment and regular tumor evaluation scans until disease progression, or until treatment is stopped for another reason.
All patients will be followed for survival until the end of the study. Independent data monitoring committee (DMC) composed of independent experts will be convened to confirm the safety and tolerability of Saruparib + physicians choice NHA.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 1800
- Male ≥ 18 years of age
- Histologically documented prostate adenocarcinoma which is de novo or recurrent and castration-sensitive. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible.
- Metastatic disease as documented by the investigator prior to randomisation, with clear evidence of ≥ 1 bone lesion and/or ≥ 1 soft tissue lesion that is suitable for repeated assessment with CT and/or MRI.
- Participant is receiving ADT with a GnRH analogue or has undergone bilateral orchiectomy starting ≥ 14 days and < 4 months prior to randomisation
- ECOG performance status of 0 or 1 with no deterioration over the 2 weeks prior to randomisation.
- Provision of FFPE tumour tissue sample and blood sample (for ctDNA)
- Confirmed HRRm status by central tumour tissue and/or ctDNA test is required to
determine cohort eligibility
- Adequate organ and bone marrow function as described in study protocol
- Participants must not father children or donate sperm from signing ICF, during the study intervention and for 6 months after the last dose of study intervention.
- Participants must use a condom from signing ICF, during study intervention, and for 6 months after the last dose of study drug, with all sexual partners.
- Participants with a history of MDS/AML or with features suggestive of MDS/AML
- Participants with any known predisposition to bleeding
- Any history of persisting (> 2 weeks) severe cytopenia
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305 and/or the assigned NHA.
- History of another primary malignancy, with exceptions
- Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy.
- Spinal cord compression or brain metastases unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to start of study intervention
- Cardiac criteria, including history of arrythmia and cardiovascular disease
- Any prior anticancer pharmacotherapy or surgery for metastatic prostate cancer, with exceptions:
- Prior treatment within 14 days with blood product support or growth factor support.
- Participants who are unevaluable for both bone and soft tissue progression
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 2: Placebo + Physician's Choice NHA Enzalutamide Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) Arm 1: Saruparib (AZD5305) + Physician's Choice NHA Enzalutamide Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) Arm 1: Saruparib (AZD5305) + Physician's Choice NHA Abiraterone Acetate Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) Arm 2: Placebo + Physician's Choice NHA Placebo Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) Arm 1: Saruparib (AZD5305) + Physician's Choice NHA Saruparib Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) Arm 1: Saruparib (AZD5305) + Physician's Choice NHA Darolutamide Saruparib (AZD5305) + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) Arm 2: Placebo + Physician's Choice NHA Abiraterone Acetate Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide) Arm 2: Placebo + Physician's Choice NHA Darolutamide Placebo + physician's choice NHA (Abiraterone, Darolutamide, or Enzalutamide)
- Primary Outcome Measures
Name Time Method Radiographic Progression-Free Survival (rPFS) up to approximately 50 months rPFS is defined as the time from randomisation to radiographic progression, as assessed by the investigator per RECIST 1.1 (soft tissue) and/or PCWG3 criteria (bone), or, death due to any cause.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) up to approximately 90 months OS is defined as the time from randomisation until the date of death due to any cause.
Second Progression-Free Survival (PFS2) up to approximately 50 months Time from randomisation to PFS2 is defined as the time from randomisation to the earliest of progression (defined as radiographic progression, clinical progression, or PSA progression) after initiation of first subsequent treatment following the initial investigator-assessed progression or death.
Time to First Subsequent Therapy or Death (TFST) up to approximately 50 months TFST is defined as the time from randomisation to the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause.
Symptomatic Skeletal Event-Free Survival (SSE-FS) up to approximately 50 months SSE-FS is defined as the time from randomisation to the earliest of the following:
* Use of radiation therapy to prevent or relieve skeletal symptoms.
* Occurrence of new symptomatic pathological bone fractures (vertebral or non-vertebral).
* Occurrence of spinal cord compression.
* Orthopaedic surgical intervention for bone metastasis.
* Death due to any cause.Time to the First Castration-Resistant Event (TTCR) up to approximately 50 months TTCR is defined as the time from randomisation to the first castration resistant event (radiographic disease progression per RECIST 1.1 \[soft tissue\] and/or PCWG3 criteria \[bone\], PSA progression per PCWG3, or SSE, PSA progression per PCWG3, or SSE), whichever occurs first, with castrate levels of testosterone (below 50 ng/dL).
Time to Pain Progression (TTPP) up to approximately 50 months TTPP is defined as the time from randomisation to clinically meaningful pain progression based on a 2-point increase from baseline in the Brief Pain Inventory - Short Form (BPI-SF) Item 3 'worst pain in 24 hours' score and/or initiation of/increase in opioid analgesic use.
Time To Deterioration in Urinary Symptoms (TTDUS) up to approximately 50 months TTDUS is defined as the time from randomisation to deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Prostate Questionnaire (Urinary Symptoms) (QLQPR25 \[US\]) subscale scores.
Time to Deterioration in Fatigue (TTDF) up to approximately 50 months TTDF is defined as the time from randomisation to deterioration in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7A scores.
Time to Deterioration in Physical Function (TTDPF) up to approximately 50 months TTDPF is defined as the time from randomisation to deterioration in PROMIS Physical Function Short Form 8C scores.
Health-related Quality of Life (HrQoL) up to approximately 50 months Change from baseline in BPI-SF worst pain score, pain severity, and interference domain scores.
BRCA and other HRR gene mutation status. at screening Plasma concentrations of AZD5305 up to approximately 10 months Samples will be used to develop complementary or companion diagnostics by analyzing their performance characteristics and calculate their consistency with clinical trial assays used for enrolment onto the study. up to approximately 50 months Samples will be tested by a CDx to certify consistency with assays used in the study.
Assessment of PSA (prostate-specific antigen) in participants in mCSPC up to approximately 50 months proportion of participants achieving a \>= 50% or \>=90% decrease in PSA from baseline; proportion of participants with undetectable PSA (\< 0.2 ng/mL); time to PSA progression
Trial Locations
- Locations (1)
Research Site
🇬🇧Truro, United Kingdom